Another example of the use of

Pharmaceuticals, newly recognized Alogliptin Benzoate of environmental pollutants, are becoming increasingly problematic contaminants of either surface water or ground water around industrial and residential communities. The presence of pharmaceuticals and personal care products (PPCPs) was first identified in surface and wastewaters in the United States and Europe in 1960s [1]. Concerns about their potential risk were raised in 1999 [2] with the issue attracting considerable interest after the presence of pharmaceuticals in river water was linked to feminization of fish living downstream of wastewater treatment plants (WWTPs) outfalls [3]. Furthermore, a link between a non-steroidal anti-inflammatory drug, diclofenac and the renal failure of vultures contributing to the > 95% decline in its population in the Indian subcontinent since the 1990's has been reported [4]. Public awareness was raised after a study showed that organic wastewater contaminants, including PPCPs, were present in 80% of 139 U.S. streams [5]. Although the concentration levels of PPCPs found in the environment are at trace concentrations, their chemical persistence, microbial resistance and synergistic effects are still unknown [6] and [7], which is a cause for concern. Moreover, low concentrations can elicit adverse effects on aquatic life [8] and [9].